Overall, our present study suggests that, in addition to the GABAergic inhibitory system, GlyRs are also altered in the hippocampus of APP/PS1 mice, which in turn might contribute to AD pathogenesis—and thus should be considered in the design of future therapeutic approaches. Here, GARS1 is linked to Alzheimer disease.